Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares Outstanding
Ratios

Avalo Therapeutics (AVTX) Other Gross PP&E Adjustments (2016 - 2025)

Avalo Therapeutics filings provide 12 years of Other Gross PP&E Adjustments readings, the most recent being -$15000.0 for Q4 2025.

  • On a quarterly basis, Other Gross PP&E Adjustments fell 102.08% to -$15000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was -$15000.0, a 102.08% decrease, with the full-year FY2025 number at -$15000.0, down 102.08% from a year prior.
  • Other Gross PP&E Adjustments hit -$15000.0 in Q4 2025 for Avalo Therapeutics, up from -$402000.0 in the prior quarter.
  • In the past five years, Other Gross PP&E Adjustments ranged from a high of $722000.0 in Q4 2024 to a low of -$1.9 million in Q1 2022.
  • Median Other Gross PP&E Adjustments over the past 5 years was -$809500.0 (2021), compared with a mean of -$750950.0.
  • Biggest five-year swings in Other Gross PP&E Adjustments: plummeted 159.74% in 2022 and later skyrocketed 64.71% in 2025.
  • Avalo Therapeutics' Other Gross PP&E Adjustments stood at $587000.0 in 2021, then decreased by 0.85% to $582000.0 in 2022, then increased by 23.37% to $718000.0 in 2023, then rose by 0.56% to $722000.0 in 2024, then tumbled by 102.08% to -$15000.0 in 2025.
  • The last three reported values for Other Gross PP&E Adjustments were -$15000.0 (Q4 2025), -$402000.0 (Q3 2025), and -$487000.0 (Q2 2025) per Business Quant data.